About
Daya CNS develops novel non-opioid pyridoindole small molecule therapeutics targeting chronic pain, neuropathies, arthritis, substance abuse disorders, and neuropsychiatric conditions such as schizophrenia.
Explore Daya CNS's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.